| 4:00–8:00 PM | Registration | 3rd Floor Foyer |
| 6:00–8:00 PM | Welcome Mixer | 3rd Floor Foyer |
| 7:00–8:00 AM | Breakfast | Summit Gallery |
| 8:00–8:10 AM | Welcome Remarks (Joint) | Colorado Ballroom |
| 8:10–9:00 AM | Keynote Address (Joint) | Colorado Ballroom |
| Alexandra Trkola, University of Zürich HIV Vaccines: Learning from the Swiss X-BNAb Cohort for Prevention and Cure |
| 9:00–11:30 AM | Immune Interventions Interfacing HIV Prevention and Cure (Joint) | Colorado Ballroom |
| Mauricio A. Martins, University of Florida Promoting Persistent bNAb Expression in NHPs through AAV-Mediated Gene Transfer |
| Devi SenGupta, Gilead Sciences, Inc. Long-acting ART in HIV Prevention and Cure |
| Leonidas Stamatatos, Fred Hutchinson Cancer Research Center Vaccination of PLWH, using 426C Derived Immunogens |
| Cristina Ceriani, Emory University Short Talk: Influence of SIV Gag Vaccination on CD8⁺ T Cell Immunity and SIV Viral Dynamics |
| Nicolas M S Galvez Arriagada, Ragon Institute of Mass General, MIT and Harvard Short Talk: Vectored Delivery of bNAbs Prevents Rebound of Clinical HIV Isolate During Antiretroviral Therapy Interruption |
| 9:30–9:50 AM | Coffee Break | 1st Floor Foyer |
| 9:50–9:55 AM | Award Recipient Acknowledgement | Colorado Ballroom |
| 11:30–12:00 PM | Los Alamos HIV Immunology and Sequence Databases User Workshop | Colorado Ballroom |
| 11:35–1:00 PM | Poster Setup | Peaks 1 - 3 |
| 11:35–2:30 PM | On Own for Lunch |
| 1:00–10:00 PM | Poster Viewing | Peaks 1 - 3 |
| 2:30–4:30 PM | Symposia Spotlight 1: Driving CD4bs Antibodies Forward | Colorado Ballroom |
| Matthew Clark, Duke University Cross-Clade HIV-1 Neutralizing Antibodies With Characteristics of bNAbs, Including VRC01, in Children |
| Xuejun Chen, NIAID, National Institutes of Health Three Sequential Escalating-Dose Immunizations Elicit VRC01-Class Antibody-Mediated Tier 2 HIV-1 Serum Neutralization in a Highly Stringent Mouse Model |
| Ria Goswami, Weill Cornell Medicine Germline-Targeting HIV SOSIP Trimer Immunizations Dampened Post-Rebound SHIV Loads in Infant Macaques |
| James A Counts †, Duke University Sequential Vaccination Elicits VH1-46 Class Orthologous Antibodies with Heterologous Reactivity and Neutralization Targeting the CD4-Binding Site In Rhesus Macaques |
| Anna Romanov, Massachusetts Institute of Technology DNA Origami Vaccines Program Antigen-Focused Germinal Centers |
| Christopher A Cottrell, The Scripps Research Institute Sequential Boosting with mRNA/LNP Immunogens Drives VRC01-Class Precursors B Cells To Acquire Key Mutations Allowing For Binding To Heterologous Wildtype HIV Env Trimers with the N276 Glycan |
| Tom G Caniels, Amsterdam UMC A Germline-Targeting Prime-Boost Regimen Drives Heterologous Neutralization Breadth of VRC01-class B Cells |
| Jerome M Edwards, Fred Hutchinson Cancer Center A Germline-Targeting Env-derived Immunogen Activates both VRC01- and CH235-class Naïve B Cells in a Phase 1 Clinical Trial |
| 4:30–5:00 PM | Coffee Available | 3rd Floor Foyer |
| 5:00–7:00 PM | Keeping up with the Changing HIV Envelope | Colorado Ballroom |
| Penny L Moore, University of the Witwatersrand and National Institute for Communicable Diseases African bNAb Immunogens |
| Margaret E. Ackerman, Dartmouth College Fc Effector Function in HIV Infection and Vaccination |
| Aime Marcel Simon Tongo Passo, Center for Research on Emerging and Re-Emerging Diseases (CREMER/IMPM) Viral Diversity in Central Africa: Known and Unknowns |
| Gnana Gnanakaran, Los Alamos National Laboratory Short Talk: Conformation of HIV Env Trimer on Intact Virions |
| Ashwin N Skelly, University of Pennsylvania Short Talk: Consistent Induction of V3-Glycan Broadly Neutralizing Antibodies by a Novel Two-Step Mechanism Informs Immunogen Design |
| 7:00–8:00 PM | Social Hour with Dinner | Summit Gallery |
| 7:30–10:00 PM | Poster Session 1 | Peaks 1 - 3 |
| 7:00–8:00 AM | Breakfast | Summit Gallery |
| 8:00–11:00 AM | The Vaccine Pipeline: Integrating Basic and Clinical Insights | Colorado Ballroom |
| Florian Klein †, Uniklinik Koeln Talk Title to be Announced |
| Richard T. Wyatt, The Scripps Research Institute Triggering bNAbs in Non-Human Primates |
| Persephone Borrow, University of Oxford Creating an Immune Environment Favorable for HIV-1 bnAb Induction |
| Louis J. Picker, Oregon Health & Science University Progress in CMV based Vaccines |
| Hlelolwenkosi Z Mlimi, University of KwaZulu-Natal - Nelson R. Mandela School of Medicine Short Talk: Immunological and Genetic Features Associated with The Development of Broadly Neutralizing Antibodies and Fc-Effector Functions in People Living with HIV-1 Subtype C |
| Lily Zemelko, University of California - San Francisco (UCSF) Short Talk: HIV DNA Therapeutic Vaccination Durably Boosts HIV-Specific CD8+ T Cell Magnitude and Proliferative Responses |
| 9:00–9:20 AM | Coffee Break | 3rd Floor Foyer |
| 11:00–1:00 PM | Poster Setup | Peaks 1 - 3 |
| 11:00–5:00 PM | On Own for Lunch |
| 1:00–10:00 PM | Poster Viewing | Peaks 1 - 3 |
| 1:30–2:45 PM | Health Equity Panel (joint) sponsored by The Burroughs Wellcome Fund | Colorado Ballroom |
| 3:00–4:30 PM | Career Roundtable (Joint) | Colorado Ballroom |
| 4:30–5:00 PM | Coffee Available | 3rd Floor Foyer |
| 5:00–7:00 PM | Targeting the Needle in the Haystack: Clinical Trials of Germline Targeting Immunogens | Colorado Ballroom |
| Kevin O. Saunders, Duke University Induction of HCDR3-Binding and CD4 Mimicking Antibodies in HVTN300 and HVTN309 |
| Eunice Wambui Nduati, KEMRI, Wellcome Trust Germline Targeting Immunogens and Precursors in African Populations |
| Marit van Gils, Amsterdam UMC Germline Targeting Immunogens in Human Clinical Trials; C101, C107, C110 |
| Rachael Parks, Fred Hutch Short Talk: N332-GT5 Germline-Targeting Immunogen Elicits BG18-bnAb Precursors in a Phase I, Human Clinical Trial (HVTN 144) |
| Catarina Mendes Silva, Amsterdam UMC Short Talk: Proof-of-Concept Induction of HIV Broadly Neutralizing Antibody Lineages by Vaccination In Humans |
| 7:00–8:00 PM | Social Hour with Dinner | Summit Gallery |
| 7:30–10:00 PM | Poster Session 2 | Peaks 1 - 3 |
| 7:00–8:00 AM | Breakfast | Summit Gallery |
| 8:00–11:00 AM | Looking to the Future: New Tools, Platforms and Delivery Systems | Colorado Ballroom |
| Eric A. Appel, Stanford University Injectable Hydrogel Depot Technologies for Sustained Delivery of Vaccines |
| Mangala Rao †, USMHRP, Walter Reed Army Institute of Research Talk Title to be Announced |
| Rory Henderson, Duke University Large Language Models to Identify bnAbs and Design Vaccines to Them |
| Nitesh Mishra, The Scripps Research Institute Short Talk: De Novo, Machine Learning Enabled Discovery of Broadly Neutralizing Unmutated Human Antibodies Against HIV-1 |
| Hongying Duan †, NIH/VRC Short Talk: Vaccine Elicitation of HIV-1 Cross-strain Neutralizing Antibodies Against Both V2 Apex and Fusion Peptide in Rhesus Macaques |
| Austin Kriews, The Wistar Institute Short Talk: Exposure to the HIV-1 gp41 Base Redirects the Specificity of Broadly Neutralizing Antibody Lineages |
| Kshitij Wagh, Duke University Short Talk: Induction of V2-apex Broadly-Neutralizing Antibodies by Signature-Based Prime and Boost mRNA Immunogens in Rhesus Macaques |
| 9:00–9:20 AM | Coffee Break | 3rd Floor Foyer |
| 11:00–5:00 PM | On Own for Lunch |
| 1:15–2:15 PM | Meet the Editors (Joint) | Colorado Ballroom |
| 2:30–4:30 PM | Symposia Spotlight 2: Looking Beyond the CD4bs | Colorado Ballroom |
| Fabian-Alexander Schleich, Karolinska Institutet Vaccination Of Nonhuman Primates Elicits a Broadly Neutralizing Antibody Lineage Targeting a Quaternary Epitope on the HIV-1 Env trimer |
| Joshua Carter, Stanford University Minimally Mutated Silent Face Antibodies Enable Germline-targeted Vaccine Design for the Silent Face Epitope |
| Rumi Habib, University of Pennsylvania Env-Antibody Coevolution Identifies B Cell Priming as the Principal Bottleneck to HIV-1 V2 Apex Broadly Neutralizing Antibody Development |
| Severin Coleon, Duke Human Vaccine Institute (DHVI) Priming Diverse V2 Apex Antibodies with Unique HCDR3 Motifs Using Germline-Targeting HIV-1 Env Ferritin Nanoparticles in Rhesus Macaques |
| Lorie Marchitto, University of Pennsylvania Enhanced B Cell Priming Leads to Rapid Induction of Broadly Neutralizing HIV-1 Apex Antibodies |
| Tianling Ou, Broad Institute Sequential Immunogens Drive Affinity Maturation of HIV-1 V2-Apex Broadly Neutralizing Antibody Precursors |
| Kevin Wiehe, Duke University Reliable Elicitation of Broadly Neutralizing Antibodies in the Serum of V3 Glycan bnAb UCA Knock-in Mice Immunized with a 4-Immunogen Vaccine Regimen |
| Jon Steichen †, The Scripps Research Institute Germline-Targeting Vaccination Elicits HIV Broadly Neutralizing Antibodies In Nonhuman Primates |
| 4:30–5:00 PM | Coffee Available | 1st Floor Foyer |
| 5:00–6:30 PM | B Cell Responses and Broadly-Neutralizing Antibodies: Trials and Tribulations (Joint) | Colorado Ballroom |
| Marina F. Caskey, Rockefeller University Combined Immunotherapy with IL-15 Agonists and Broadly-Neutralizing Antibodies |
| Paula M Cannon, University of Southern California, Keck School of Medicine Engineering B Cells as in vivo bnAb Factories |
| William Schief, Moderna, Scripps, and IAVI Combining Germline Targeting Approaches Across Diverse bNAb Epitopes |
| 6:30–6:45 PM | Meeting Wrap-Up: Outcomes and Future Directions (Organizers) | Colorado Ballroom |
| 6:45–7:45 PM | Social Hour with Dinner | Summit Gallery |
| 7:45–8:45 PM | Entertainment |
| 8:00–9:00 PM | Cash Bar | Peaks 1 - 3 |
| 12:00–11:59 PM | Departure |